OR WAIT null SECS
December 20, 2024
Article
Tirzepatide's approval marks the first and only prescription medicine available for adults with moderate-to-severe obstructive sleep apnea and obesity.
August 27, 2024
Allegheny Health Network (AHN) implants innovative device to manage central sleep apnea in heart failure patients, reducing mortality rise and improving quality of life.
August 23, 2024
Nocturnal hypoxia may represent an additional modifiable risk factor for AMD, particularly its neovascular form.
July 18, 2024
Younger adults (aged 20 – 40 years) with OSA were 3 times more likely to experience any type of CVD event than those without OSA.
July 03, 2024
Video
Gozal told HCPLive about the issue of the classic approach when diagnosing children with OSA.
June 21, 2024
Atul Malhotra, MD, discusses the results of the SURMOUNT-OSA trial and how they inform clinicians on the role of tirzepatide in OSA and obesity.
June 02, 2024
A cohort analysis suggests upper airway collapsibility prevalence may correlate closely to race in patients with OSA.
New study data show patients with OSA may use a fixed CPAP device for a longer daily duration than those with an automatic option.
June 01, 2024
New data presented at SLEEP 2024 show sleep disorders including insomnia are only linked to worse quality of life when veterans do not also have PTSD.
New analysis from SURMOUNT-1 support the use of GLP-1/GIP agonist tirzepatide to reduce weight in patients with OSA and obesity/overweight.
